8021 The effect of anemia on the progression-free survival in epithelial ovarian cancer (stage II-IV) patients treated with paclitaxel-carboplatin combination therapy: a retrospective analysis of the JGOG3016 trial of the Japanese Gynecologic Oncology Group (JGOG3016-A)

2009 ◽  
Vol 7 (2) ◽  
pp. 456
Author(s):  
T. Sugiyama ◽  
S. Kumagai ◽  
T. Shouji ◽  
H. Michimae ◽  
N. Katsumata ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Combination Therapy ◽  
Epithelial Ovarian Cancer ◽  
Retrospective Analysis ◽  
Gynecologic Oncology ◽  
Progression Free Survival ◽  
Gynecologic Oncology Group ◽  
Cancer Stage ◽  
Oncology Group ◽  
Free Survival

Consolidation therapy revisited: intravenous chemotherapy

2003 ◽  
Vol 13 (Suppl 2) ◽  
pp. 204-207 ◽  
Author(s):  
M. Markman
Keyword(s):  
Ovarian Cancer ◽  
Gynecologic Oncology ◽  
Single Agent ◽  
Progression Free Survival ◽  
Gynecologic Oncology Group ◽  
Consolidation Therapy ◽  
Oncology Group ◽  
Intravenous Chemotherapy ◽  
Free Survival ◽  
Cumulative Toxicity

The administration of ‘consolidation’ therapy is designed to maximize the benefits achieved from primary chemotherapy, to both improve progression-free and overall survival. Paclitaxel is an excellent agent to consider for a consolidation strategy in ovarian cancer, based on its activity in the disease, its cycle-specificity, and the lack of serious cumulative toxicity (except for neuropathy). A recently reported randomized trial conducted by the South-west Oncology Group and the Gynecologic Oncology Group revealed that 12-monthly cycles of single-agent paclitaxel (175 mg/m2 over 3 h) improves progression-free survival (PFS), compared to 3-monthly cycles of the agent (median PFS: 28 months versus 21 months, P = 0.0023, and hazard ratio 2.31). Further exploration of consolidation/maintenance therapy in the management of ovarian cancer is indicated, focusing on agents that are easy to administer (eg, oral) and that result in limited cumulative toxicity.

Does Severe Anemia Caused by Dose-Dense Paclitaxel-Carboplatin Combination Therapy Have an Effect on the Survival of Patients With Epithelial Ovarian Cancer? Retrospective Analysis of the Japanese Gynecologic Oncology Group 3016 Trial

2011 ◽  
Vol 21 (9) ◽  
pp. 1585-1591 ◽  
Author(s):  
Seisuke Kumagai ◽  
Toru Sugiyama ◽  
Tadahiro Shoji ◽  
Hirofumi Michimae ◽  
Noriyuki Katsumata ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Gynecologic Oncology ◽  
Progression Free Survival ◽  
Gynecologic Oncology Group ◽  
Severe Anemia ◽  
Free Survival ◽  
Median Progression Free Survival ◽  
Grade 3 ◽  
Dose Dense

IntroductionTo evaluate the incidence of anemia in patients with epithelial ovarian cancer receiving paclitaxel-carboplatin combination therapy (TC) using data from the Japanese Gynecologic Oncology Group (JGOG) 3016 trial, and to examine the effect of severe anemia on survival during dose-dense TC.MethodsRetrospective analysis was conducted in patients enrolled in the JGOG 3016 trial who underwent at least one cycle of the protocol therapy (n = 622). Hemoglobin values at enrollment and during each cycle of TC were collected. One-to-one matching was performed between patients with and patients without grade 3/4 anemia during TC (anemia and nonanemia groups) to adjust the baseline characteristics of the patients. The cumulative survival curve and median progression-free survival were estimated using the Kaplan-Meier method.ResultsGrades 2 to 4 anemia was observed in 19.8% of patients before first-line TC. The incidence of grade 3/4 anemia rapidly increased to 56.1% after the fourth cycle of dose-dense TC. After matching, the median progression-free survival in the anemia (hemoglobin <8.0 g/dL) and nonanemia (hemoglobin >8.0 g/dL) groups was 777 and 1100 days, respectively (P = 0.3493) for patients receiving dose-dense TC. The median progression-free survival in patients receiving conventional TC was similar between the 2 groups.ConclusionsThe difference in progression-free survival between patients with epithelial ovarian cancer with and those without severe anemia during TC was not statistically significant, but for patients receiving dose-dense TC, severe anemia seems to have prognostic relevance. Prospective trials are needed to investigate whether the optimal management of chemotherapy-induced anemia, including appropriate use of erythropoiesis-stimulating agents, would further improve the survival of patients with ovarian cancer receiving dose-dense TC.

scholarly journals Bevacizumab use in the frontline, maintenance and recurrent settings for ovarian cancer

2020 ◽  
Vol 16 (7) ◽  
pp. 225-246 ◽  
Author(s):  
Carolyn E Haunschild ◽  
Krishnansu S Tewari
Keyword(s):  
Ovarian Cancer ◽  
Gynecologic Oncology ◽  
Progression Free Survival ◽  
Phase Iii ◽  
Gynecologic Oncology Group ◽  
Double Blind ◽  
Free Survival ◽  
Platinum Sensitive ◽  
The Us ◽  
Us Fda

On 13 June 2018, Genentech, Inc. issued a press release announcing that the US FDA had approved the antiangiogenesis drug, bevacizumab, in combination with chemotherapy for frontline and maintenance therapy for women with newly diagnosed ovarian cancer. Regulatory approval was based on the National Cancer Institute-sponsored Gynecologic Oncology Group (GOG) protocol 0218, the Phase III, randomized, placebo-controlled, double-blind, multi-center and multi-national clinical trial that met its primary end point, progression-free survival. Bevacizumab is now approved in the frontline, platinum-sensitive recurrent and platinum-resistant recurrent settings for epithelial ovarian cancer. This review will address the broad range of clinical trials addressing the efficacy of bevacizumab use in ovarian cancer.

Maspin expression in epithelial ovarian cancer and associations with poor prognosis: A Gynecologic Oncology Group study

2006 ◽  
Vol 101 (3) ◽  
pp. 390-397 ◽  
Author(s):  
Angeles Alvarez Secord ◽  
Paula S. Lee ◽  
Kathleen M. Darcy ◽  
Laura J. Havrilesky ◽  
Lisa A. Grace ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Poor Prognosis ◽  
Gynecologic Oncology ◽  
Gynecologic Oncology Group ◽  
Oncology Group ◽  
Oncology Group Study ◽  
Maspin Expression
Sign in / Sign up

Export Citation Format

Share Document